Compare Stocks: QNCX, ONCY, ACET, and BMEA

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ACET Adicet Bio	$7.98 +0.6%	$8.33	$6.01 ▼ $17.44	$74.13M	1.6	96,267 shs	80,392 shs
BMEA Biomea Fusion	$1.26 +0.8%	$1.27	$0.87 ▼ $2.99	$90.37M	-0.28	567,316 shs	426,622 shs
ONCY Oncolytics Biotech	$0.80 +0.2%	$0.87	$0.73 ▼ $1.51	$95.56M	1.13	1.43 million shs	566,366 shs
QNCX Quince Therapeutics	$30.20 +2.2%	$19.90	$15.10 ▼ $909.98	$30.04M	1.36	40,143 shs	30,291 shs

The Best Nuclear Energy Stocks to Buy

Nuclear energy is entering a new growth cycle as rising power demand, expanding data centers, and renewed policy support bring the sector back into focus. After strong gains in recent years, the most impactful phase of nuclear investment may still be ahead. This report highlights seven nuclear energy stocks positioned across the value chain—combining near-term revenue with long-term upside as next-generation technologies scale. Click the link below to unlock the full list.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ACET Adicet Bio	+0.63%	-12.40%	-13.73%	-6.67%	-28.84%
BMEA Biomea Fusion	+0.80%	+7.69%	-3.08%	-18.18%	-20.75%
ONCY Oncolytics Biotech	+0.24%	+6.53%	+1.29%	-9.82%	-13.71%
QNCX Quince Therapeutics	+2.23%	+29.12%	+75.07%	+17.97%	-90.90%

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ACET Adicet Bio	$7.98 +0.6%	$8.33	$6.01 ▼ $17.44	$74.13M	1.6	96,267 shs	80,392 shs
BMEA Biomea Fusion	$1.26 +0.8%	$1.27	$0.87 ▼ $2.99	$90.37M	-0.28	567,316 shs	426,622 shs
ONCY Oncolytics Biotech	$0.80 +0.2%	$0.87	$0.73 ▼ $1.51	$95.56M	1.13	1.43 million shs	566,366 shs
QNCX Quince Therapeutics	$30.20 +2.2%	$19.90	$15.10 ▼ $909.98	$30.04M	1.36	40,143 shs	30,291 shs

The Best Nuclear Energy Stocks to Buy

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ACET Adicet Bio	+0.63%	-12.40%	-13.73%	-6.67%	-28.84%
BMEA Biomea Fusion	+0.80%	+7.69%	-3.08%	-18.18%	-20.75%
ONCY Oncolytics Biotech	+0.24%	+6.53%	+1.29%	-9.82%	-13.71%
QNCX Quince Therapeutics	+2.23%	+29.12%	+75.07%	+17.97%	-90.90%

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
ACET Adicet Bio	2.75	Moderate Buy	$46.80	486.47% Upside
BMEA Biomea Fusion	2.67	Moderate Buy	$8.20	550.79% Upside
ONCY Oncolytics Biotech	2.75	Moderate Buy	$8.50	959.19% Upside
QNCX Quince Therapeutics	2.27	Hold	$568.40	1,782.12% Upside

Current Analyst Ratings Breakdown

Latest QNCX, ONCY, ACET, and BMEA Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
8/6/2026	ACET Adicet Bio	Guggenheim Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy	$100.00 ➝ $90.00
7/29/2026	QNCX Quince Therapeutics	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Sell (E+)
7/29/2026	QNCX Quince Therapeutics	Oppenheimer Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Initiated Coverage	Outperform	$82.00
7/14/2026	ONCY Oncolytics Biotech	HC Wainwright Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy
7/13/2026	ONCY Oncolytics Biotech	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Sell (E+) ➝ Sell (D-)
7/1/2026	BMEA Biomea Fusion	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Sell (D-) ➝ Sell (E+)
6/29/2026	QNCX Quince Therapeutics	Lifesci Capital Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Strong-Buy
6/25/2026	ONCY Oncolytics Biotech	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Sell (D-) ➝ Sell (E+)
6/24/2026	QNCX Quince Therapeutics	Zacks Research Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Hold
6/24/2026	QNCX Quince Therapeutics	Leerink Partners Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Initiated Coverage	Outperform	$80.00
6/23/2026	QNCX Quince Therapeutics	Cantor Fitzgerald Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Initiated Coverage	Overweight	$80.00

(Data available from 8/8/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
ACET Adicet Bio	N/A	N/A	N/A	N/A	$12.85 per share	N/A
BMEA Biomea Fusion	N/A	N/A	N/A	N/A	$0.17 per share	N/A
ONCY Oncolytics Biotech	N/A	N/A	N/A	N/A	($0.04) per share	N/A
QNCX Quince Therapeutics	N/A	N/A	N/A	N/A	($128.18) per share	N/A

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
ACET Adicet Bio	-$116.80M	-$11.45	N/A	N/A	N/A	N/A	-74.90%	-60.87%	N/A
BMEA Biomea Fusion	-$61.80M	-$0.68	N/A	N/A	N/A	N/A	-253.73%	-97.91%	N/A
ONCY Oncolytics Biotech	-$28.76M	-$0.31	N/A	N/A	N/A	N/A	-2,185.97%	-321.54%	8/14/2026 (Estimated)
QNCX Quince Therapeutics	-$83.98M	-$212.40	N/A	N/A	N/A	N/A	N/A	-67.99%	8/11/2026 (Estimated)

Latest QNCX, ONCY, ACET, and BMEA Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/11/2026	Q2 2026	QNCX Quince Therapeutics	-$28.02	N/A	N/A	N/A	N/A	N/A
8/6/2026	Q2 2026	BMEA Biomea Fusion	-$0.2235	-$0.12	+$0.1035	-$0.12	N/A	N/A
8/5/2026	Q2 2026	ACET Adicet Bio	-$1.69	-$1.99	-$0.30	-$1.99	N/A	N/A
5/14/2026	Q1 2026	ONCY Oncolytics Biotech	-$0.05	-$0.08	-$0.03	-$0.08	N/A	N/A
5/13/2026	Q1 2026	ACET Adicet Bio	-$2.93	-$1.88	+$1.05	-$1.88	N/A	N/A
5/11/2026	Q1 2026	BMEA Biomea Fusion	-$0.24	-$0.17	+$0.07	-$0.17	N/A	N/A
5/11/2026	Q1 2026	QNCX Quince Therapeutics	-$26.00	-$0.59	+$25.41	$57.60	N/A	N/A

Compare Dividends

Company	Annual Payout	Dividend Yield	5-Year Annualized Dividend Growth	Payout Ratio	Years of Consecutive Growth
ACET Adicet Bio	$0.04	0.50%	N/A	N/A	N/A
BMEA Biomea Fusion	N/A	N/A	N/A	N/A	N/A
ONCY Oncolytics Biotech	N/A	N/A	N/A	N/A	N/A
QNCX Quince Therapeutics	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
ACET Adicet Bio	0.01	6.71	7.65
BMEA Biomea Fusion	N/A	3.47	4.98
ONCY Oncolytics Biotech	N/A	1.38	1.38
QNCX Quince Therapeutics	N/A	2.92	2.92

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
ACET Adicet Bio	83.89%
BMEA Biomea Fusion	96.72%
ONCY Oncolytics Biotech	6.82%
QNCX Quince Therapeutics	30.75%

Insider Ownership

Company	Insider Ownership
ACET Adicet Bio	3.40%
BMEA Biomea Fusion	10.60%
ONCY Oncolytics Biotech	0.10%
QNCX Quince Therapeutics	7.10%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
ACET Adicet Bio	90	9.35 million	9.03 million	Optionable
BMEA Biomea Fusion	50	72.30 million	64.64 million	Optionable
ONCY Oncolytics Biotech	30	119.35 million	119.24 million	Not Optionable
QNCX Quince Therapeutics	60	1.02 million	945,000	Optionable

QNCX, ONCY, ACET, and BMEA Headlines

Recent News About These Companies

Quince Therapeutics, Inc. (NASDAQ:QNCX) Receives Average Rating of "Hold" from Brokerages

August 5 at 2:58 AM | americanbankingnews.com

Oppenheimer Begins Coverage on Quince Therapeutics (NASDAQ:QNCX)

July 31, 2026 | americanbankingnews.com

Quince Therapeutics

July 6, 2026 | fool.com

Quince Therapeutics Stock Short Interest Report | NASDAQ:QNCX | Benzinga

July 2, 2026 | benzinga.com

Quince Therapeutics Appoints Recognized Leaders in Pulmonary Medicine to Scientific Advisory Board

June 30, 2026 | globenewswire.com

Quince Therapeutics, Inc. (QNCX) Shareholder/Analyst Call Prepared Remarks Transcript

June 11, 2026 | seekingalpha.com

Quince Therapeutics Inc. (QNCX) Presents Positive Phase 2a Data for LAM-001 Inhaled Therapy

June 2, 2026 | insidermonkey.com

Quince Therapeutics Regains Nasdaq Compliance, Avoids Delisting Risk

May 24, 2026 | theglobeandmail.com

Quince Therapeutics, Inc. (QNCX) M&A Call Prepared Remarks Transcript

May 18, 2026 | seekingalpha.com

UPDATE - Quince Therapeutics Announces Clinically Meaningful Improvements Across Functional, Hemodynamic and Biomarker Measures in Phase 2 Study in PAH and PH-ILD

May 18, 2026 | globenewswire.com

Quince Therapeutics Announces Clinically Meaningful Improvements Across Functional, Hemodynamic and Biomarker Measures in Phase 2 Study in PAH and PH-ILD

May 18, 2026 | globenewswire.com

Quince Announces Acquisition of Orphai and up to $187 Million Private Placement to Advance Pulmonary Pipeline

May 18, 2026 | globenewswire.com

Quince Therapeutics (QNCX) price target increased by 100.00% to 81.60

May 15, 2026 | msn.com

Quince Therapeutics (QNCX) price target increased by 900.00% to 40.80

April 28, 2026 | msn.com

Quince Therapeutics Delays Annual 10-K Filing

April 27, 2026 | theglobeandmail.com

Quince Therapeutics settles $16.4M debt with $5.5M payment

March 30, 2026 | msn.com

Why did QNCX stock surge 40% in pre-market today?

March 30, 2026 | msn.com

Quince Therapeutics Settles Approximately $16.4 Million of Debt

March 30, 2026 | businesswire.com

Bankruptcy threat looms as Quince runs out of options

February 13, 2026 | pharmaphorum.comP

Quince Therapeutics stock plummets after revealing strategic alternatives

February 13, 2026 | au.investing.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

QNCX, ONCY, ACET, and BMEA Company Descriptions

Adicet Bio NASDAQ:ACET

$7.98 +0.05 (+0.63%)

Closing price 08/7/2026 04:00 PM Eastern

Extended Trading

$8.18 +0.20 (+2.44%)

As of 08/7/2026 07:34 PM Eastern

Adicet Bio, Inc., a clinical stage biotechnology company, discovers and develops allogeneic gamma delta T cell therapies for autoimmune diseases and cancer. The company offers gamma delta T cells engineered with chimeric antigen receptors (CARs) to facilitate durable activity in patients. Its lead product candidate is ADI-001, an allogeneic gamma delta T cell therapy expressing a CAR targeting CD20, which is in Phase I clinical trial for the treatment of autoimmune diseases and relapsed or refractory aggressive B cell non-Hodgkin's lymphoma. The company is also developing ADI-270, an armored gamma delta CAR T cell product candidate targeting renal cell carcinoma for treating other CD70+ solid tumor and hematological malignancies indications. The company was founded in 2014 and is based in Boston, Massachusetts.

Biomea Fusion NASDAQ:BMEA

$1.26 +0.01 (+0.80%)

Closing price 08/7/2026 04:00 PM Eastern

Extended Trading

$1.26 +0.00 (+0.40%)

As of 08/7/2026 07:34 PM Eastern

Biomea Fusion, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of covalent small molecule drugs to treat patients with genetically defined cancers and metabolic diseases. Its lead product candidate is BMF-219, a covalent inhibitor of menin for treating patients with liquid and solid tumors and type 2 diabetes. The company was incorporated in 2017 and is headquartered in Redwood City, California.

Oncolytics Biotech NASDAQ:ONCY

$0.80 +0.00 (+0.24%)

Closing price 08/7/2026 04:00 PM Eastern

Extended Trading

$0.81 +0.01 (+1.18%)

As of 08/7/2026 07:56 PM Eastern

Oncolytics Biotech Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of pharmaceutical products for the treatment of cancer. The company is developing pelareorep, an intravenously delivered immunotherapeutic agent, which is in phase 3 clinical trial for the treatment of hormone receptor-positive / human epidermal growth factor 2-negative metastatic breast cancer and advanced/metastatic pancreatic ductal adenocarcinoma. It has a co-development agreement with Merck KGaA and Pfizer Inc. to co-develop pelareorep, as well as with Roche Holding AG. The company was incorporated in 1998 and is headquartered in Calgary, Canada.

Quince Therapeutics NASDAQ:QNCX

$30.20 +0.66 (+2.23%)

Closing price 08/7/2026 04:00 PM Eastern

Extended Trading

$29.00 -1.20 (-3.98%)

As of 08/7/2026 07:39 PM Eastern

Quince Therapeutics, Inc., a biopharmaceutical company, focuses on acquiring, developing, and commercializing therapeutics for patients with debilitating and rare diseases. The company's lead asset candidature comprises EryDex for the treatment of rare pediatric neurodegenerative disease, including A-T, an inherited autosomal recessive neurodegenerative and immunodeficiency disorder caused by mutations in ATM gene. Its AIDE technology platform, a drug/device combination platform that uses an automated process to encapsulate a drug into a patient's own red blood cells, as well as consists of an automated equipment the RCL, a sterile single-use consumable treatment kit comprising EryKit, Syringe Kit, drugs, and process solutions. The company was formerly known as Cortexyme, Inc. and changed its name to Quince Therapeutics, Inc. in August 2022. Quince Therapeutics, Inc. was incorporated in 2012 and is headquartered in South San Francisco, California.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest QNCX, ONCY, ACET, and BMEA Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest QNCX, ONCY, ACET, and BMEA Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

QNCX, ONCY, ACET, and BMEA Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

QNCX, ONCY, ACET, and BMEA Company Descriptions

Adicet Bio NASDAQ:ACET

Biomea Fusion NASDAQ:BMEA

Oncolytics Biotech NASDAQ:ONCY

Quince Therapeutics NASDAQ:QNCX

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest QNCX, ONCY, ACET, and BMEA Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest QNCX, ONCY, ACET, and BMEA Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

QNCX, ONCY, ACET, and BMEA Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

QNCX, ONCY, ACET, and BMEA Company Descriptions

Adicet Bio NASDAQ:ACET

Biomea Fusion NASDAQ:BMEA

Oncolytics Biotech NASDAQ:ONCY

Quince Therapeutics NASDAQ:QNCX

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools